AU6902200A - Novel methods of diagnosis of angiogenesis, compositions and methods of screening for angiogenesis modulators - Google Patents

Novel methods of diagnosis of angiogenesis, compositions and methods of screening for angiogenesis modulators

Info

Publication number
AU6902200A
AU6902200A AU69022/00A AU6902200A AU6902200A AU 6902200 A AU6902200 A AU 6902200A AU 69022/00 A AU69022/00 A AU 69022/00A AU 6902200 A AU6902200 A AU 6902200A AU 6902200 A AU6902200 A AU 6902200A
Authority
AU
Australia
Prior art keywords
angiogenesis
methods
diagnosis
screening
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU69022/00A
Other languages
English (en)
Inventor
Richard Murray
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
EOS Biotechnology Inc
Original Assignee
EOS Biotechnology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by EOS Biotechnology Inc filed Critical EOS Biotechnology Inc
Publication of AU6902200A publication Critical patent/AU6902200A/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5064—Endothelial cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2550/00—Electrophoretic profiling, e.g. for proteome analysis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pathology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Physiology (AREA)
AU69022/00A 1999-08-11 2000-08-11 Novel methods of diagnosis of angiogenesis, compositions and methods of screening for angiogenesis modulators Abandoned AU6902200A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14842599P 1999-08-11 1999-08-11
US60148425 1999-08-11
PCT/US2000/022061 WO2001011086A2 (en) 1999-08-11 2000-08-11 Methods of screening for angiogenesis modulators

Publications (1)

Publication Number Publication Date
AU6902200A true AU6902200A (en) 2001-03-05

Family

ID=22525710

Family Applications (1)

Application Number Title Priority Date Filing Date
AU69022/00A Abandoned AU6902200A (en) 1999-08-11 2000-08-11 Novel methods of diagnosis of angiogenesis, compositions and methods of screening for angiogenesis modulators

Country Status (6)

Country Link
EP (1) EP1204764A2 (es)
JP (1) JP2003517816A (es)
AU (1) AU6902200A (es)
CA (1) CA2381699A1 (es)
MX (1) MXPA02001439A (es)
WO (1) WO2001011086A2 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7803765B2 (en) 1999-05-05 2010-09-28 Phylogica Limited Methods of constructing biodiverse gene fragment libraries and biological modulators isolated therefrom
US7034132B2 (en) 2001-06-04 2006-04-25 Anderson David W Therapeutic polypeptides, nucleic acids encoding same, and methods of use
GB0002201D0 (en) 2000-01-31 2000-03-22 Imperial College Process
US6855690B2 (en) 2000-06-01 2005-02-15 Children's Medical Center Corporation Methods and compositions for treating ocular disorders
JP2008001720A (ja) * 2002-06-21 2008-01-10 Japan Science & Technology Agency アンサマイシン系抗生物質の新規用途及び新規血管新生抑制物質のスクリーニング方法
JP4393098B2 (ja) * 2002-06-21 2010-01-06 独立行政法人科学技術振興機構 アンサマイシン系抗生物質の新規用途及び新規血管新生抑制物質のスクリーニング方法
US7285268B2 (en) 2002-11-26 2007-10-23 Pdl Biopharma, Inc. Chimeric and humanized antibodies to α5β1 integrin that modulate angiogenesis
US7276589B2 (en) 2002-11-26 2007-10-02 Pdl Biopharma, Inc. Chimeric and humanized antibodies to α5β1 integrin that modulate angiogenesis
US7871610B2 (en) 2003-08-12 2011-01-18 Dyax Corp. Antibodies to Tie1 ectodomain
US7485297B2 (en) 2003-08-12 2009-02-03 Dyax Corp. Method of inhibition of vascular development using an antibody
WO2005069855A2 (en) 2004-01-13 2005-08-04 Rigel Pharmaceuticals, Inc. Modulators of angiogenesis
BRPI0509177A (pt) 2004-03-24 2007-09-18 Pdl Biopharma Inc uso de anticorpos anti-alfa5beta1 para inibir a proliferação de células cancerìgenas
CA2568644C (en) 2004-06-03 2015-11-24 Phylogica Limited Peptide modulators of cellular phenotype and bi-nucleic acid fragment library
JP5576610B2 (ja) 2006-02-20 2014-08-20 フィロジカ リミテッド ペプチド構造のライブラリーの構築およびスクリーニング方法
MX2008011905A (es) 2006-03-21 2008-09-30 Genentech Inc Terapia de combinacion.
CA2663545A1 (en) 2006-09-19 2008-03-27 Phylogica Limited Neuroprotective peptide inhibitors of ap-1 signaling and uses thereof
US8822409B2 (en) 2007-06-20 2014-09-02 Phylogica Limited Compositions and uses thereof for the treatment of acute respiratory distress syndrome (ARDS) and clinical disorders associated with therewith
SI2200700T1 (sl) 2007-09-26 2016-04-29 Genentech, Inc. Nova protitelesa
RU2011142974A (ru) 2009-03-25 2013-04-27 Дженентек, Инк. НОВЫЕ АНТИТЕЛА ПРОТИВ α5β1 И ИХ ПРИМЕНЕНИЕ
BR112013014119A8 (pt) 2010-12-08 2017-07-11 Stem Centrx Inc Novos moduladores e métodos de uso
JP2012125194A (ja) * 2010-12-16 2012-07-05 Mie Univ 腫瘍血管新生制御遺伝子
TW201605480A (zh) 2013-11-04 2016-02-16 輝瑞大藥廠 抗ｅｆｎａ４抗體－藥物結合物
US10883108B2 (en) 2016-03-31 2021-01-05 The Schepens Eye Research Institute, Inc. Endomucin inhibitor as an anti-angiogenic agent

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1173991C (zh) * 1992-11-13 2004-11-03 马克斯普朗克科学促进协会 作为血管内皮生长因子受体的f1k-1
AU2066797A (en) * 1996-03-21 1997-10-10 Sugen, Inc. Assays for kdr/flk-1 receptor tyrosine kinase inhibitors
JP4121155B2 (ja) * 1996-12-27 2008-07-23 中外製薬株式会社 新規なセリン／スレオニンキナーゼ遺伝子
AU7348998A (en) * 1997-05-16 1998-12-08 Hospital For Sick Children, The Inhibition of angiogenesis by verotoxins
AU9304498A (en) * 1997-09-04 1999-03-22 Incyte Pharmaceuticals, Inc. New vrk1 kinase
EP1019080A2 (en) * 1997-10-02 2000-07-19 Leukosite, Inc. Modulation of lerk-2-mediated cell adhesion
EP1051511A1 (en) * 1998-01-29 2000-11-15 Merck & Co., Inc. Methods of identifying modulators of kinases responsive to stress

Also Published As

Publication number Publication date
WO2001011086A9 (en) 2002-07-11
WO2001011086A3 (en) 2002-03-07
WO2001011086A2 (en) 2001-02-15
EP1204764A2 (en) 2002-05-15
MXPA02001439A (es) 2002-08-30
JP2003517816A (ja) 2003-06-03
CA2381699A1 (en) 2001-02-15

Similar Documents

Publication Publication Date Title
WO2002079492A8 (en) Methods of diagnosis of angiogenesis, compositions and methods of screening for angiogenesis modulators
AU6902200A (en) Novel methods of diagnosis of angiogenesis, compositions and methods of screening for angiogenesis modulators
AU6497600A (en) Peracid forming system, peracid forming composition, and methods for making and using
AU2002215345A1 (en) Methods of diagnosis of prostate cancer, compositions and methods of screening for modulators of prostate cancer
AU2002245317A1 (en) Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer
AU2002309583A1 (en) Methods of diagnosis of lung cancer, compositions and methods of screening for modulators of lung cancer
AU2002330039A1 (en) Methods of diagnosis of cancer compositions and methods of screening for modulators of cancer
AUPQ419099A0 (en) Novel compositions and methods
AU3867400A (en) Methods of using bioelastomers
AU2002249871A1 (en) Novel methods of diagnosing breast cancer, compositions, and methods of screening for breast cancer modulators
WO2003022987A9 (en) Methods of diagnosis of hepatitis c infection, compositions and methods of screening for modulators of hepatitis c infection
AU3752700A (en) Novel methods of diagnosing and treating breast cancer, compositions, and methods of screening for breast cancer modulators
AU3755300A (en) Novel methods of diagnosing colorectal cancer, compositions, and methods of screening for colorectal cancer modulators
AU2106001A (en) Methods and compositions for screening for angiogenesis modulating compounds
AU7902400A (en) Method for the preparation of 5-carboxyphthalide
AU2001290902A1 (en) Methods of diagnosis of colorectal cancer, compositions and methods of screening for colorectal cancer modulators
AU7433900A (en) Screening methods
AU6432800A (en) Process for the synthesis of citalopram
AU1718301A (en) Use of sugar compositions
AU2982000A (en) Preparation of 9-hydrocarbyl-9-phosphabicyclononanes
AU2002357734A1 (en) Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer
AU5179800A (en) Mycolactone and related compounds, compositions and methods of use
AU1037901A (en) Process for the preparation of paroxetine
AU1601801A (en) Methods of preparing crna
AU6152700A (en) Novel isoforms of the human estrogen receptor-alpha

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase